New drug safety check for liver patients

NCT ID NCT07559474

Recruiting now Knowledge-focused Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study looks at how a new drug, INCB123667, behaves in the bodies of 16 adults with moderate or severe liver disease. Researchers will measure drug levels and watch for side effects. The goal is to gather safety information, not to treat the liver condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma Hepatic Insufficiency liver disorder liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC INSUFFICIENCY LIVER DISEASES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Arizona Clinical Trials - the Institute For Liver Health
RECRUITING

Chandler, Arizona, 85225, United States
Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States
Pinnacle Clinical Research
RECRUITING

San Antonio, Texas, 78229, United States
Texas Liver Institute - American Research Corporation
RECRUITING

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.